Is Healthcare Services Group (HCSG) Outperforming Other Business Services Stocks This Year?
Healthcare Services is a member of the Business Services sector. This group includes 271 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Healthcare Services is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for HCSG's full-year earnings has moved 13.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that HCSG has returned about 22.7% since the start of the calendar year. Meanwhile, the Business Services sector has returned an average of -0.3% on a year-to-date basis. This means that Healthcare Services is outperforming the sector as a whole this year.
Loop Industries, Inc. (LOOP) is another Business Services stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 30.8%.
In Loop Industries, Inc.'s case, the consensus EPS estimate for the current year increased 2.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Healthcare Services belongs to the Business - Services industry, a group that includes 26 individual companies and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 18.3% so far this year, meaning that HCSG is performing better in terms of year-to-date returns.
On the other hand, Loop Industries, Inc. belongs to the Technology Services industry. This 130-stock industry is currently ranked #51. The industry has moved +7.5% year to date.
Investors with an interest in Business Services stocks should continue to track Healthcare Services and Loop Industries, Inc. These stocks will be looking to continue their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Healthcare Services Group, Inc. (HCSG) : Free Stock Analysis Report
Loop Industries, Inc. (LOOP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Law Offices of Frank R. Cruz Encourages Lineage, Inc. (LINE) Investors to Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Lineage, Inc. ('Lineage' or the 'Company') (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement used in connection with the Company's July 2024 initial public offering (the 'IPO'). Lineage investors have until September 30, 2025 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Lineage, Inc. (LINE) Investors To Inquire About Securities Fraud Class Action Share IF YOU SUFFERED A LOSS ON YOUR LINEAGE, INC. (LINE) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@ by telephone at (310) 914-5007, or visit our website at What Happened? In July 2024, Lineage conducted its IPO, selling over 65 million shares of common stock at $78 per share. On November 6, 2024, Lineage released its third quarter 2024 financial results, revealing that it had suffered a $543 million net loss during the quarter. On this news, Lineage's stock price fell $5.22, or 7.4%, to close at $65.79 per share on November 6, 2024, thereby injuring investors. Then, on January 14, 2025, The Wall Street Journal reported that Lineage was laying off employees due to reduced customer demand only six months after its IPO. Then, on April 7, 2025, Lineage announced the dismissal of its auditor, KPMG LLP. On this news, Lineage's stock price fell $5.29, or 9.9%, over two consecutive trading days, to close at $48.41 per share on April 8, 2025. Then, on April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.16, or 14.62%, to close at $47.65 per share on April 30, 2025, thereby injuring investors further. On June 3, 2025, the Company stated at an Investor Conference that there has been 'pretty much flat demand' for Lineage's products and services and that the Company was operating in a 'flattish environment' in terms of demand. The price of Lineage stock has remained substantially below the IPO price at the time of this complaint's filing. What Is The Lawsuit About? The complaint filed in this class action alleges that the Registration Statement made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) that Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (3) that Lineage was unable to effectively counteract the adverse trends listed in the foregoing through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) that, as a result of the foregoing, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the Registration Statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Lineage common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: info@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
Investcorp Credit Management BDC, Inc. Schedules Earnings Release for the Second Quarter Ended June 30, 2025
NEW YORK--(BUSINESS WIRE)--Investcorp Credit Management BDC, Inc. (NASDAQ:ICMB) ('ICMB' or 'Company') today announced that it will release its financial results for the second quarter ended June 30, 2025 on Tuesday, August 12, 2025, after the close of the financial markets. The Company will host an earnings conference call at 10:00 am (Eastern Time) on Wednesday, August 13, 2025 to review its financial results and conduct a question-and-answer session. All interested parties may participate in the conference call by dialing (800) 550-9893 5-10 minutes prior to the call; international callers should dial (858) 609-8959. Participants should enter 872058# as the passcode, then press 2 when prompted. For those who are not able to listen to the call, a replay will be available shortly after the call by visiting our website at About Investcorp Credit Management BDC, Inc. The Company is an externally-managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing in debt and related equity investments of privately held middle-market companies. The Company seeks to invest primarily in middle-market companies that have annual revenues of at least $50 million and earnings before interest, taxes, depreciation, and amortization of at least $15 million. The Company's investment activities are managed by its investment adviser, CM Investment Partners LLC. To learn more about Investcorp Credit Management BDC, Inc., please visit Forward-Looking Statements Statements included herein or on the conference call may contain "forward-looking statements," which relate to future performance or ICMB's financial condition, are based upon current expectations and are inherently uncertain. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of assumptions, risks and uncertainties and other factors, some of which are beyond the Company's control, including the impact of significant market volatility on the Company's business, its portfolio companies, its industry and the global economy. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein, except as required by law. All forward-looking statements speak only as of the date of this press release.
Yahoo
an hour ago
- Yahoo
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has been one of the most searched-for stocks on lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned -4.2% over the past month versus the Zacks S&P 500 composite's +2.7% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has lost 7.7% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Revisions to Earnings Estimates Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Pfizer is expected to post earnings of $0.81 per share for the current quarter, representing a year-over-year change of -23.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.4%. For the current fiscal year, the consensus earnings estimate of $3.11 points to no change from the prior year. Over the last 30 days, this estimate has changed +2.3%. For the next fiscal year, the consensus earnings estimate of $3.09 indicates a change of -0.8% from what Pfizer is expected to report a year ago. Over the past month, the estimate has remained unchanged. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Pfizer. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth Forecast While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Pfizer, the consensus sales estimate of $17.23 billion for the current quarter points to a year-over-year change of -2.7%. The $63.64 billion and $62.88 billion estimates for the current and next fiscal years indicate changes of +0% and -1.2%, respectively. Last Reported Results and Surprise History Pfizer reported revenues of $14.65 billion in the last reported quarter, representing a year-over-year change of +10.3%. EPS of $0.78 for the same period compares with $0.6 a year ago. Compared to the Zacks Consensus Estimate of $13.78 billion, the reported revenues represent a surprise of +6.35%. The EPS surprise was +34.48%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Valuation Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Pfizer is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. Bottom Line The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about Pfizer. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
